Dexrazoxane

Cytoprotective Agent — VARIOUS

Key facts

Dexrazoxane is an ofp drug in the Cytoprotective Agent class catalogued in DrugCentral. It was first approved by the FDA in 1995. DrugCentral lists 2 molecular targets, including TOP2A and TOP2B. Recorded indications include Doxorubicin Induced Cardiomyopathy, Extravasation Injury from Anthracycline Injection and Prevention of CMV Disease After Organ Transplant.

• Approval status: ofp (first approved 1995 by the FDA).
• Drug class: Cytoprotective Agent.
• Molecular targets: TOP2A and TOP2B (2 listed in DrugCentral).
• Indications: Doxorubicin Induced Cardiomyopathy, Extravasation Injury from Anthracycline Injection and Prevention of CMV Disease After Organ Transplant.
• ATC code: V03AF02 (Detoxifying agents for antineoplastic treatment).
• Molecular formula: C11H16N4O4; molecular weight 268.27 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (3)

• Doxorubicin Induced Cardiomyopathy
• Extravasation Injury from Anthracycline Injection
• Prevention of CMV Disease After Organ Transplant

Contraindications (3)

• Bone marrow depression
• Impaired renal function disorder
• Non-infective meningitis

Mechanism & targets

• Established pharmacologic class: Cytoprotective Agent

Molecular targets (2)

Target	Gene	Action	Activity
DNA topoisomerase 2-alpha	TOP2A	unknown	IC50 4.40
DNA topoisomerase 2-beta	TOP2B	unknown	IC50 4.30

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
1995-05-26	FDA	—	PHARMACIA AND UPJOHN	Yes

ATC classification

ATC code	Therapeutic hierarchy
V03AF02	VARIOUS › ALL OTHER THERAPEUTIC PRODUCTS › ALL OTHER THERAPEUTIC PRODUCTS › Detoxifying agents for antineoplastic treatment

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Febrile neutropenia	1049.6
Lymphoid tissue hypoplasia	338.0
Thymus hypoplasia	329.5
Disseminated aspergillosis	283.4
Off label use	223.8
Clostridium difficile colitis	220.3
Aplastic anaemia	173.3
Cytomegalovirus viraemia	163.8
Lymphopenia	143.8
Fungal infection	139.1
Bacterial infection	138.0
Neutropenia	134.6

Chemical structure

• Molecular formula: C₁₁H₁₆N₄O₄
• Molecular weight: 268.27 g/mol
• CAS number: 24584-09-6
• InChIKey: BMKDZUISNHGIBY-ZETCQYMHSA-N
• PubChem CID: 71384

C[C@@H](CN1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Dexrazoxane used for?

DrugCentral lists the following indications for Dexrazoxane: Doxorubicin Induced Cardiomyopathy, Extravasation Injury from Anthracycline Injection and Prevention of CMV Disease After Organ Transplant.

How does Dexrazoxane work?

Its molecular targets in DrugCentral include TOP2A and TOP2B.

When was Dexrazoxane first approved?

Dexrazoxane was first approved by the FDA in 1995.

What drug class does Dexrazoxane belong to?

Dexrazoxane is in the Cytoprotective Agent class.

What is the chemical formula of Dexrazoxane?

Dexrazoxane has the molecular formula C11H16N4O4 and a molecular weight of 268.27 g/mol.

Sources

• DrugCentral drug card 839 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL1200778 — compound record and bioactivity
• PubChem CID 71384 — chemical identifiers
• DrugBank DB00380 — drug record
• FDA UNII 048L81261F — substance identity
• DailyMed: FDA labels for Dexrazoxane — current prescribing information (label search)
• UniProt P11388 (TOP2A) — target protein
• UniProt Q02880 (TOP2B) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.